Skip to main content
Clinical Trials/NCT01073605
NCT01073605
Completed
Phase 3

A Two Years Multicentre Study of Genotropin Treatment of Short Prepubertal Children With Intra-Uterine Growth Retardation

Pfizer1 site in 1 country208 target enrollmentJuly 1993

Overview

Phase
Phase 3
Intervention
Genotonorm
Conditions
Growth Disorders
Sponsor
Pfizer
Enrollment
208
Locations
1
Primary Endpoint
Change From Baseline in Annual Growth Rate Measured at 2 Years Following Treatment With Genotonorm
Status
Completed
Last Updated
15 years ago

Overview

Brief Summary

To evaluate the effect of continuous and intermittent administration of Genotonorm on stature in short prepubertal children with intra-uterine growth retardation

Registry
clinicaltrials.gov
Start Date
July 1993
End Date
May 2009
Last Updated
15 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Pfizer

Eligibility Criteria

Inclusion Criteria

  • Chronological age (CA) between 3 and 10 for girls
  • Chronological age between 3 and 12 for boys
  • Height for CA below - 2 SD
  • Birth length for CA below -2SD

Exclusion Criteria

  • Endocrine disease except well-substituted hypothyroidism
  • Sever chronic disease
  • Skeletal dysplasia
  • Known chromosomal aberration
  • Ongoing treatment with steroids
  • Known intrauterine infection

Arms & Interventions

Genotonorm A

Continuous 0.7 IU/kg/week or 0.03 mg/kg/day

Intervention: Genotonorm

Genotonorm B

Continuous, 1.4 IU/kg/week or 0.06 mg/kg/day

Intervention: Genotonorm

Genotonorm C

Intermittent, 1.4 IU/kg/week or 0.06 mg/kg/day

Intervention: Genotonorm

Outcomes

Primary Outcomes

Change From Baseline in Annual Growth Rate Measured at 2 Years Following Treatment With Genotonorm

Time Frame: Baseline, 2 years

Annual growth rate was expressed as height velocity (centimeter \[cm\]/year). This was derived by substracting annual growth rate at Baseline from 2-year value. (Annual growth rate was calculated each year and rescaled to 1 year if the interval between x and x-1 was not 365 days, as long as a subject remains in the study): ANGRYx = (Height Yx - Height Y{x-1}) / {(Date of Yx - Date of Y{x-1}) /365.25}

Secondary Outcomes

  • Annual Growth Rate Standard Deviation Score (SDS)(Baseline, 1 to 6 years)
  • Change From Baseline in Annual Growth Rate SDS(Baseline, 1 to 3 years)
  • Height (cm)(Baseline, 1 to 6 years, final height)
  • Change From Baseline in Height (cm)(Baseline, 1 to 6 years, final height)
  • Height (SDS)(Baseline, 1 to 6 years, final height)
  • Change From Baseline in Height (SDS)(Baseline, 1 to 6 years, final height)
  • Body Mass Index (BMI)(Baseline, 1 to 6 years)
  • Weight(Baseline, 1 to 6 years)
  • Change From Baseline in Bone Age(Baseline, 1 to 3 years)
  • Change From Baseline in Bone Age/Change From Baseline in Chronological Age Ratio(1 to 3 years)
  • Chronological Age at Onset of Puberty(Onset of puberty)
  • Number of Subjects Reaching Puberty(Baseline, 1 to 6 years)

Study Sites (1)

Loading locations...

Similar Trials